Ritonavir Oral: Booster Dosing and Precautions
Ritonavir booster guidance for protease inhibitors in HIV infection, with hepatic and interaction precautions.
Also searched as
Source reviewed
November 2022
Guide category
Oral drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Therapeutic action
Antiretroviral, HIV protease inhibitor.
Indications
Booster for protease inhibitors such as atazanavir, darunavir, and lopinavir in HIV infection. Ritonavir should not be used alone.
Forms and strengths
- 25 mg tablet.
- 100 mg tablet.
Dose
Dosage depends on the administration schedule of the boosted protease inhibitor. The daily dose is administered once daily or in 2 divided doses.
- Child 14 to under 25 kg: 50 mg 2 times daily, or 100 mg once daily.
- Child 25 kg and over and adult: 100 mg once or 2 times daily.
Duration
Depending on the efficacy and tolerance of the boosted protease inhibitor and ritonavir.
Contra-indications, adverse effects, precautions
- Do not administer to patients with severe hepatic impairment.
- Administer with caution and monitor use in patients with haemophilia or mild to moderate hepatic impairment.
- The adverse effects of ritonavir as a booster are also dependent on the boosted protease inhibitor.
- May cause gastrointestinal disturbances, fatigue, headache, dizziness, paraesthesia, joint and muscle pain, taste disturbances, hyperglycaemia, hyperlipidaemia, lipodystrophy, conduction disorders, pancreatitis, hepatic disorders, and severe skin rash.
- Ritonavir reduces the efficacy of implants and oral contraceptives. Use injectable medroxyprogesterone or an intrauterine device.
- Pregnancy: no contra-indication.
- Take with meals.
- Tablets are not recommended in children under 14 kg.
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Rate this guide
Be the first to rate this guide.
